Astrocyte-aberrant reactive features involving a decrease in GFAP and GLT-1 levels, an increased proliferative capacity, and an elevated expression of the Cx43 and S100B signature [20,21], together with inflammatory astrocytic markers [36,61], were identified in rodent and human ALS models. The gene discussed is SLC1A2; the disease is amyotrophic lateral sclerosis.